Publication: High mobility group box 1 and interleukin 6 at intensive care unit admission as biomarkers in critically Ill COVID-19 Patients
Issued Date
2021-07-01
Resource Type
ISSN
14761645
00029637
00029637
Other identifier(s)
2-s2.0-85109727077
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
American Journal of Tropical Medicine and Hygiene. Vol.105, No.1 (2021), 73-80
Suggested Citation
Chaisith Sivakorn, Jutamas Dechsanga, Lawan Jamjumrus, Kobporn Boonnak, Marcus J. Schultz, Arjen M. Dondorp, Weerapong Phumratanaprapin, Ranistha Ratanarat, Thummaporn Naorungroj, Patchrapa Wattanawinitchai, Tanaya Siripoon, Chatnapa Duangdee, Tachpon Techarang High mobility group box 1 and interleukin 6 at intensive care unit admission as biomarkers in critically Ill COVID-19 Patients. American Journal of Tropical Medicine and Hygiene. Vol.105, No.1 (2021), 73-80. doi:10.4269/ajtmh.21-0165 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/77264
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
High mobility group box 1 and interleukin 6 at intensive care unit admission as biomarkers in critically Ill COVID-19 Patients
Abstract
Exuberant inflammation manifesting as a “cytokine storm” has been suggested as a central feature in the pathogenesis of severe coronavirus disease 2019 (COVID-19). This study investigated two prognostic biomarkers, the high mobility group box 1 (HMGB1) and interleukin-6 (IL-6), in patients with severe COVID-19 at the time of admission in the intensive care unit (ICU). Of 60 ICU patients with COVID-19 enrolled and analyzed in this prospective cohort study, 48 patients (80%) were alive at ICU discharge. HMGB1 and IL-6 plasma levels at ICU admission were elevated compared with a healthy control, both in ICU nonsurvivors and ICU survivors. HMGB1 and IL-6 plasma levels were higher in patients with a higher Sequential Organ Failure Assessment (SOFA) score (> 10), and the presence of septic shock or acute kidney injury. HMGB1 and IL-6 plasma levels were also higher in patients with a poor oxygenation status (PaO2/FiO2 < 150 mm Hg) and a longer duration of ventilation (> 7 days). Plasma HMGB1 and IL-6 levels at ICU admission also correlated with other prognostic markers, including the maximum neutrophil/lymphocyte ratio, D-dimer levels, and C-reactive protein levels. Plasma HMGB1 and IL-6 levels at ICU admission predicted ICU mortality with comparable accuracy to the SOFA score and the COVID-GRAM risk score. Higher HMGB1 and IL-6 were not independently associated with ICU mortality after adjustment for age, gender, and comorbidities in multivariate analysis models. In conclusion, plasma HMGB1 and IL6 at ICU admission may serve as prognostic biomarkers in critically ill COVID-19 patients.